Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…
In an observational comparative effectiveness study of targeted vs non-targeted therapy for metastatic renal cell carcinoma (mRCC), older patients saw modest survival advantages when treated with targeted therapies.…
Antoine Azar, MD, clinical director of the Division of Allergy and Immunology at Johns Hopkins Bayview Medical Center, discusses a patient’s journey to diagnosis and treatment of adult…
In this video, Dr. Daniel George, MD, discusses the results of a sunitinib study that helped change the treatment landscape for renal cell carcinoma (RCC). Compared to placebo,…
An interim analysis of the CHECKMATE920 phase IIIb/IV clinical trial found that renal cell carcinoma (RCC) patients with brain metastasis show encouraging anti-tumor activity in response to nivolumab…
